N-Nitroso Fedratinib Impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Fedratinib is used to treat adults with certain types of myelofibrosis (MF; a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production). Fedratinib is in a class of medications called kinase inhibitors.N-Nitroso Fedratinib Impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
N-Nitroso Fedratinib Impurity 1 CAS NO:NA Chemically represented as N-(Tert-butyl)-3-((5-methyl-2-(nitroso(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl) (nitroso) amino) benzenesulfonamide .Synchemia is the leading manufacturing and exporter of N-Nitroso Fedratinib Impurity 1.We supply N-Nitroso Fedratinib Impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0141907 |
| CAS No | NA |
| Mol.F. | C20H22N6O5 |
| Mol.Wt. | 426.4g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141908 |
| CAS No | NA |
| Mol.F. | C20H24N6O4 |
| Mol.Wt. | 412.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141909 |
| CAS No | NA |
| Mol.F. | C18H20N6O3 |
| Mol.Wt. | 368.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141910 |
| CAS No | NA |
| Mol.F. | C18H19N7O4 |
| Mol.Wt. | 397.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141911 |
| CAS No | NA |
| Mol.F. | C26H22FN3O2 |
| Mol.Wt. | 427.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141912 |
| CAS No | NA |
| Mol.F. | C33H33FN3O6 |
| Mol.Wt. | 586.6 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141913 |
| CAS No | NA |
| Mol.F. | C15H17N3O2 |
| Mol.Wt. | 271.3 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0141914 |
| CAS No | NA |
| Mol.F. | C16H21ClN4O2 |
| Mol.Wt. | 336.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141915 |
| CAS No | NA |
| Mol.F. | C16H21ClN4O |
| Mol.Wt. | 320.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141916 |
| CAS No | NA |
| Mol.F. | C16H20ClN3O3 |
| Mol.Wt. | 337.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141917 |
| CAS No | NA |
| Mol.F. | C16H20ClN5O3 |
| Mol.Wt. | 365.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141918 |
| CAS No | NA |
| Mol.F. | C18H25ClN4O3 |
| Mol.Wt. | 380.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141919 |
| CAS No | NA |
| Mol.F. | C16H21ClN4O |
| Mol.Wt. | 320.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141920 |
| CAS No | NA |
| Mol.F. | C14H16ClN3O2 |
| Mol.Wt. | 293.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141921 |
| CAS No | NA |
| Mol.F. | C18H25ClN4O5S |
| Mol.Wt. | 444.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141922 |
| CAS No | NA |
| Mol.F. | C20H27ClN4O3 |
| Mol.Wt. | 406.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |